1. 1047PDPembrolizumab for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of treatment options from the phase III KEYNOTE-040 trial. (23rd October 2018) Authors: Le Tourneau, C; Cohen, E E W; Harrington, K J; Dinis, J; Licitra, L; Ahn, M -J; Soria, A; Machiels, J-P; Mach, N; Mehra, R; Burtness, B; Zhang, P; Cheng, J; Swaby, R; Soulières, D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1082PProgrammed death-ligand 1 (PD-L1) expression and HPV-associated p16 in oropharyngeal squamous cell carcinoma (OSCC) treated with primary curative radiotherapy (RT). (23rd October 2018) Authors: Steiniche, T; Eriksen, J G; Lilja-Fischer, J K; Georgsen, J; Vo, P-T; Busch-Sørensen, M; Chirovsky, D R; Cheng, J; Aurora-Garg, D; Swaby, R; Overgaard, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1122TiPPembrolizumab in patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC): The phase II KEYNOTE-629 study. (23rd October 2018) Authors: Licitra, L F; Siu, L L; Cohen, E E W; Zhang, P; Gumuscu, B; Swaby, R; Harrington, K Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 286OPhase III KEYNOTE-048 study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma: Asia vs non-Asia subgroup analysis. (24th November 2019) Authors: Ngamphaiboon, N; Tanaka, K; Hong, R-L; Wan Ishak, W Z; Yen, C-J; Sriuranpong, V; Takahashi, S; Srimuninnimit, V; Yeh, S-P; Oridate, N; Yang, M-H; Nohata, N; Koh, Y; Roy, A; Gumuscu, B; Swaby, R; Tahara, M Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 316TiPNeoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study. (24th November 2019) Authors: Cohen, E; Uppaluri, R; Lee, N; Westra, W; Haddad, R; Temam, S; Le Tourneau, C; Chernock, R; Safina, S; Tao, Y; Klochikhin, A; Meirovitz, A; Brana, I; Ge, J Y; Swaby, R; Bidadi, B; Adkins, D Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗